— Pasithea Clinics companions with ZEN Healthcare – a community of well being clinics in Central London – to supply ketamine infusion remedy for the remedy of psychological well being issues —
— Ketamine in sub-anesthetic doses has proven to be extremely efficient at treating some psychiatric issues, equivalent to treatment-resistant despair and post-traumatic stress dysfunction —
MIAMI BEACH, Fla., Oct. 14, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology firm targeted on the analysis and discovery of recent and efficient remedies for psychiatric and neurological issues, at present introduced that its wholly owned subsidiary, Pasithea Clinics, has partnered with ZEN Healthcare to supply intravenous (“IV”) ketamine remedy to sufferers affected by treatment-resistant psychological well being points. Initially, the remedy can be supplied in Knightsbridge, London, starting October 2021.
Pasithea Therapeutics not too long ago raised $24 million at its preliminary public providing (“IPO”). The Company’s Common Stock started buying and selling on The Nasdaq Capital Market on September 15, 2021, beneath the image “KTTA.”
Pasithea Clinics has clinic partnerships each in the United States and in the United Kingdom to supply IV ketamine remedy. In the U.Okay., it has partnered with ZEN Healthcare – a community of well being clinics in London. In the U.S., it has partnered with The IV Doc, Inc., to supply in-home IV ketamine infusions. Both partnerships supply speedy publicity and enlargement alternatives.
“With mental health cases on the rise, fueled even more so by the pandemic, new treatment therapies are urgently needed for those patients who are not responding to traditional treatments. Evidence from dozens of trials over the past two decades consistently supports the efficacy of ketamine in improving symptoms in some mental health disorders. We are thrilled to be able to provide this new treatment approach in the U.K. for those patients who are deemed eligible to receive it,” said Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.
“This launch marks a significant milestone for Pasithea Clinics and for patients in the U.K. suffering with mental health conditions. We look forward to growing our specialty clinics network while we simultaneously progress with our drug development program to move the needle forward for better mental health care,” concluded Dr. Reis Marques.
“This is an exciting opportunity for Pasithea Clinics to offer ground-breaking therapies to those who can really benefit. Our highly trained professionals are taking an integrative approach that combines the IV ketamine infusion therapy with psychiatric support. Today, there is still much misunderstanding about ketamine and its application in a psychiatric setting, but the potentially rapid and potent antidepressant effects are beginning to be recognized within the regulatory and scientific communities. People struggling with their mental health ultimately deserve to explore every avenue to recovery without social stigmas. We believe we can become the best-in-class provider of IV ketamine treatments,” mentioned Dr. Yassine Bendiabdallah, Managing Director of Pasithea Clinics in the UK.
Ketamine is a U.S. Food and Drug Administration (“FDA”) authorized drug launched to the medical group as an anesthetic greater than 50 years in the past. It has not too long ago been repurposed for the remedy of psychiatric issues utilizing considerably decrease doses than in anesthesia and is now gaining floor as a promising remedy for psychological well being issues. In sure psychiatric circumstances, equivalent to treatment-resistant despair (“TRD”) and post-traumatic stress dysfunction (“PTSD”), it has proven exceptional efficacy and a speedy and sustained impact.
Major Depression is the main reason behind long-term incapacity worldwide, in accordance with the World Health Organization, with present remedies having restricted success charges, quite a few uncomfortable side effects and onset of motion delayed by a number of weeks. Studies have proven that with IV ketamine remedy, as much as 70% of those that obtain this remedy can ultimately present a scientific response. While the variety of remedies advised is completed on a case-by-case foundation, a typical remedy plan consists of as much as six infusions in the interval of two to a few weeks.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a U.S. biotechnology firm targeted on the analysis and discovery of recent and efficient remedies for psychiatric and neurological issues. With an skilled group of consultants in the fields of neuroscience and psychopharmacology, Pasithea is creating new molecular entities for the remedy of psychiatric and neurological issues. Pasithea can also be targeted on addressing the wants of sufferers at present struggling with psychological sickness by offering entry to IV ketamine infusions each in clinics and in-home settings.
About ZEN Healthcare
ZEN Healthcare is a luxurious pharmacy and well being clinic in London with three branches – Baker Street, Knightsbridge and Holborn. The clinics comprise a multidisciplinary group of Private GPs, anti-ageing docs, pharmacists, nutritionists, dermatologists and psychotherapists, in addition to intravenous infusions specialists. ZEN Healthcare has been working pioneering IV therapies in London for six years.
Forward Looking Statements
This press launch incorporates statements that represent “forward-looking statements.” Forward-looking statements are topic to quite a few circumstances, lots of that are past the management of the Company. While the Company believes these forward-looking statements are cheap, undue reliance shouldn’t be positioned on any such forward-looking statements, that are based mostly on data out there to the Company on the date of this launch. These forward-looking statements are based mostly upon present estimates and assumptions and are topic to varied dangers and uncertainties, together with, with out limitation, these set forth in the Company’s filings with the SEC. Thus, precise outcomes might be materially totally different. The Company undertakes no obligation to replace these statements whether or not because of new data, future occasions or in any other case, after the date of this launch, besides as required by regulation.
Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
Pasithea Therapeutics Corp. Investor Relations
Lisa M. Wilson
In-Site Communications, Inc.